{"id":"dexamethasone-physician-choice","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia and mood disturbances"},{"rate":null,"effect":"Increased infection risk"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Immunosuppression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone enters cells and binds to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of inflammatory responses. It is approximately 25–30 times more potent than the natural glucocorticoid cortisol.","oneSentence":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:25.659Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus)"},{"name":"Cerebral edema and increased intracranial pressure"},{"name":"Severe COVID-19 (respiratory support requirement)"},{"name":"Chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Adrenocortical insufficiency"}]},"trialDetails":[{"nctId":"NCT06835387","phase":"PHASE2","title":"Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors","status":"RECRUITING","sponsor":"Tiago Biachi de Castria","startDate":"2025-06-30","conditions":"Small Bowel Adenocarcinoma","enrollment":36},{"nctId":"NCT01659658","phase":"PHASE3","title":"Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis","status":"TERMINATED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2012-12-26","conditions":"Relapsed or Refractory Systemic Light Chain Amyloidosis","enrollment":177},{"nctId":"NCT06731647","phase":"PHASE2","title":"Non-steroidal Anti-inflammatory Drugs in Pleurodesis","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2025-02-01","conditions":"Non-steroidal Anti-inflammatory Drugs, Pleurodesis, Pneumothorax","enrollment":358},{"nctId":"NCT03348696","phase":"PHASE4","title":"Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2018-02-28","conditions":"Early-stage Breast Cancer, Pain Syndrome","enrollment":124},{"nctId":"NCT01913990","phase":"PHASE4","title":"Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2011-09","conditions":"Emesis","enrollment":323}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["dexamethasone sodium phosphate","dexamethasone acetate"],"phase":"marketed","status":"active","brandName":"Dexamethasone physician choice","genericName":"Dexamethasone physician choice","companyName":"Ottawa Hospital Research Institute","companyId":"ottawa-hospital-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm. Used for Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus), Cerebral edema and increased intracranial pressure, Severe COVID-19 (respiratory support requirement).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}